Quality Choice Effervescent Cold Relief - Plus (Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate)

Quality Choice Effervescent Cold Relief - Plus is a over-the-counter branded nonsteroidal anti-inflammatory drug product delivering active moiety Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate (cross-referenced at /meds/aspirin-chlorpheniramine-maleate-phenylephrine-bitartrate), registered by Chain Drug Marketing Association under NDC 83324-239, 55910-769. Updated in FDA DailyMed SPL on 2026-07-15, this branded presentation (7.8 mg/1 / 325 mg/1 Tablet, Effervescent; 325 mg/1 / 2 mg/1 Tablet, Effervescent) supports Uses ■ temporarily relieves these symptoms due to the common cold: ■ sneezing ■ nasal congestion ■ sore throat ■ headache.

Pharmacologically, Quality Choice Effervescent Cold Relief - Plus derives its clinical activity from Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate, a nonsteroidal anti-inflammatory drug molecule with class-characteristic hepatorenal disposition. Branded finished-dosage manufacturing (7.8 mg/1 / 325 mg/1 Tablet, Effervescent; 325 mg/1 / 2 mg/1 Tablet, Effervescent; registered by Chain Drug Marketing Association) governs excipient dissolution and release kinetics while maintaining bioequivalence benchmarks relative to reference Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate (CMS NADAC $0.0158/unit vs. $34.50 retail).

Clinical clearance of Quality Choice Effervescent Cold Relief - Plus (Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate) (Nonsteroidal Anti-inflammatory Drug) relies on mixed metabolic conjugation and unchanged urinary excretion across quality choice effervescent cold relief - plus (aspirin, chlorpheniramine maleate, phenylephrine bitartrate) regimens with a Terminal t½ estimated at 4–9 hrs depending on renal/hepatic reserve (Quality Choice Effervescent Cold Relief - Plus (Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate)) half-life; patients absorbing at F ≈ 49%–61% systemic availability after standard oral Quality Choice Effervescent Cold Relief - Plus (Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate) administration bioavailability typically observe target onset around time to peak concentration spans 1 to 4 hrs under quality choice effervescent cold relief - plus (aspirin, chlorpheniramine maleate, phenylephrine bitartrate) maintenance.

FDA clinical labeling for Quality Choice Effervescent Cold Relief - Plus (Aspirin, Chlorpheniramine Maleate, Phenylephrine Bitartrate) restricts administration in prior anaphylaxis, angioedema, or severe hypersensitivity to aspirin, chlorpheniramine maleate, phenylephrine bitartrate or quality choice effervescent cold relief - plus (aspirin, chlorpheniramine maleate, phenylephrine bitartrate) excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-15 quality choice effervescent cold relief - plus (aspirin, chlorpheniramine maleate, phenylephrine bitartrate) spl across 7.8 mg/1 / 325 mg/1 Tablet, Effervescent, 325 mg/1 / 2 mg/1 Tablet, Effervescent, 325 mg/1 / 7.8 mg/1 Tablet, Effervescent, 7 mg/1 / 2 mg/1 Tablet, Effervescent, 7.8 mg/1 / 2 mg/1 Tablet, Effervescent, with self-reported patient tracking dominated by headache (10.4% of reports), nausea (7.3% of reports), dizziness (5.9% of reports).